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The endothelial lipase protein is promising
urinary biomarker for diagnosis of gastric cancer
Xueyan Dong1†, Guoqing Wang1†, Guoqing Zhang2, Zhaohui Ni1, Jian Suo3, Juan Cui4, Ai Cui1, Qing Yang1,
Ying Xu4,5* and Fan Li1*
Abstract
Background: Gastric cancer is one of the most common malignant tumors in the world. Finding effective
diagnostic biomarkers in urine or serum would represent the most ideal solution to detecting gastric cancer during
annual physical examination. This study was to evaluate the potential of endothelial lipase (EL) as a urinary
biomarker for diagnosis of gastric cancer.
Methods: The expression levels of EL was measured using Western blotting and immunohistochemical staining
experiments on (tissue, serum, and urine) samples of gastric cancer patients versus healthy people. We also checked
the EL levels in the urine samples of other cancer types (lung, colon and rectum cancers) and benign lesions
(gastritis and gastric leiomyoma) to check if EL was specific to gastric cancer.
Result: We observed a clear separation between the EL expression levels in the urine samples of 90 gastric cancer
patients and of 57 healthy volunteers. It was approximately 9.9 fold average decrease of the EL expression levels in
the urine samples of gastric cancer compared to the healthy controls (P <0.0001), achieving a 0.967 AUC value for
the ROC (receiver operating characteristic) curve, demonstrating it’s highly accurate as a diagnostic marker for
gastric cancer. Interestingly, the expression levels of EL in tissue and serum samples were not nearly as
discriminative as in urine samples (P = 0.90 and P = 0.79). In immunohistochemical experiments, positive expression
of the EL protein was found in 67% (8/12) of gastric adjacent noncancerous and in 58% (7/12) of gastric cancer
samples. There was no significant statistical in the expression levels of this protein between the gastric cancer and
the matching noncancerous tissues (P =0.67).
Conclusions: The urinary EL as a highly accurate gastric cancer biomarker that is potentially applicable to the
general screening with high sensitivity and specificity.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/4527331618757552
Keywords: Endothelial lipase, Biomarker, Gastric cancer, Diagnosis
Background
Gastric cancer is one of the most common malignant tu-
mors in the world, representing the third leading cause
for cancer-related death in men and the fifth leading
cause in women [1]. Approximately two-thirds of gastric
cancer cases occur in less developed countries, which
are almost three times higher per capita than in the de-
veloped countries, such as European countries and
North America [2]. Gastric cancer has high mortality
rates since it has no obvious clinical symptoms in the
early stage. Studies suggest that if the tumor was
detected and resected at the early stage, the average
5-year survival rate is relatively high [3,4]. Therefore,
early diagnosis and treatment represent a key to improv-
ing the prognosis of gastric cancer patients.
Although great amount of effort has been put into
the technology development to facilitate diagnosis using
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gastroscopy and immunohistochemical analysis, the inva-
sive nature of these procedures makes it impractical for
large-scale screening for gastric cancer. Effective diagnos-
tic biomarkers in urine or serum would represent the
most ideal solution to the problem, which allows testing
for gastric cancer through blood or urine tests during an-
nual physical examinations. Several diagnostic serum
markers have been proposed for gastric cancer, such as
MG7-Ag [5], carcinoembryonic antigen (CEA), MUC1
and MUC5AC [6]. The state of the art is that virtually all
of them suffer from rather low sensitivities and specific-
ities in cancer diagnosis, and hence have not been widely
used clinically [7]. Compared with tissue and serum, urine
collection is relatively easier and less invasive. It may be
more suitable for large scale screening for cancer detec-
tion [8]. Using comparative proteomic analyses, a number
of potential urinary biomarkers have been proposed and
well tested for other types of cancers, such as cystatin B
and clusterin for bladder cancer [9,10], carbonic anhydrase
IX and cathepsin D for renal cancer [11,12], and ADAM12
for breast cancer [13]. For gastric cancer, several bio-
markers have been reported, such as pepsinogen I, prosta-
glandin E2, and soluble c-erbB-2 [14-16]. The actual
diagnostic ability for gastric cancer is yet to be thoroughly
assessed, as they have not been widely used in clinical
diagnostic. Therefore, there is clearly an urgent need for
identification and validation of novel and reliable diagnos-
tic markers for screening gastric cancer.
We have previously carried out a system biology study
to identify potential candidate biomarkers for diagnosis
of gastric cancer. In that study, we analyzed the gene-
expression data of 80 pairs of gastric cancer tissues and
adjacent non-cancerous tissues collected from gastric
cancer patients using microarray chips, and identified
hundreds of differentially expressed genes in cancer ver-
sus control tissues [17]. We then trained a support vec-
tor machine (SVM) based classifier to predict which of
these differentially expressed genes may have their pro-
teins excreted into urine. Among the predicted excretory
protein, we found EL shows high discriminating power
in terms of its expression in urine samples of gastric
cancer patients versus healthy people [18].
Here we extend our previous study aiming to (a) fur-
ther confirm that EL has high discriminative power be-
tween urine samples of gastric cancer patients and
healthy people over a larger set of samples, and (b) dem-
onstrate that EL is highly specific to gastric cancer by
comparing its abundances in urine samples of gastric
cancer with other cancer types and benign lesions.
Methods
Sample collection
All samples were collected at three hospitals of Jilin
University Norman Bethune Medical College, Changchun,
China and at the Cancer Hospital affiliated with Xinjiang
Medical University, Urumqi, China. The gastric cancer tis-
sues and the matching non-cancerous tissues were surgi-
cally resected from gastric cancer patients. The serum and
morning random-catch urine samples were obtained from
the cancer patients before surgery. These specimen sam-
ples were collected, during the period from March 2011
to September 2012. A total of 90 gastric cancer cases
(67males and 23 females; age range: 31–85 years) and 57
healthy volunteers (30 males and 27 females; age range:
29–76 years) were studied. The gastric cancer cases were
diagnosed by histological analyses as intestinal and diffuse
type according to Lauren classification. In addition, urine
samples were obtained from 9 lung cancer patients, 10
from colon cancer patients, 10 rectum cancer patients, 2
gastritis patients, and 2 gastric leiomyoma patients, which
are used to check if EL is specific to gastric cancer. The
following criteria were used in the sample collection: (i)
cancer patients should not have started any treatment on
their cancer; and (ii) volunteers in the healthy control
group should not have any serious systemic disease in the
past. A written informed consent form was signed by each
participant after they were informed about the purpose of
the study, which was approved by the Research Ethics
Committees at Jilin University College of Medicine and
Xinjiang Medical University, respectively. Table 1 summa-
rizes the information of the healthy volunteers and pa-
tients involved in this study.
Western blotting analysis
The tissues were grinded to powder in liquid nitrogen
and then lysed in protein extraction buffer [0.5 mol/L
Tris · Cl (pH 7.4), 150 mmol/L NaCl, 0.1 mmol/L ethyl-
ene diamine tetra aceticacid (EDTA) (pH 7.0), 1 mmol/L
phenylmethylsulfonyl fluoride (PMSF), 2.5 mg/mL apro-
tinin, 1 mmol/L dithiothreitol (DTT), 1% Triton X-100,
1% sodium deoxycholate (SDS)]. All reagents were pur-
chased from Beyotime (Beyotime, Shanghai, China).
Serum and urine samples were stored in the presence of
protease inhibitor (Roche, Basel, Switzerland) sterile
containers and centrifuged (1,000 × g for 10 minutes at
4°C) to remove cellular components. The supernatants
were collected and stored at −80°C (the longest storage
for 6 months). 2 ml urine samples were dialyzed against
distilled water through a filtration membrane (Dinguo,
Beijing, China) of 8 kDa cutoff at 4°C and then lyophi-
lized at −20°C. Freeze-dried urine samples were re-
suspended in 10 mM phosphate-buffered saline (PBS)
(pH 7.5). Protein concentrations were measured using
the BCA Protein Assay Kit (Beyotime, Shanghai, China).
Urinary creatinine levels were quantized by alkaline pic-
rate method (Jaffe’s reaction) with creatinine a routine
test semi-autoanalyser (Vital Micro 300, Netherlands).
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Western blot was used to measure the expression levels
of EL. 20 μg of total proteins were used in the experiment.
All samples were separated using 4-15% SDS-PAGE (Bio-
Rad Laboratories Inc., USA) and transferred onto a PVDF
membrane (Bio-Rad Laboratories Inc., USA). The mem-
brane was incubated in 5% milk blocking solution for
2 hours at room temperature. The membrane was incu-
bated with a polyclonal goat anti-human EL primary anti-
body (1:400; Santa Cruz Biotechnologies, USA) at room
temperature for 1 hour, which was washed three times for
5 minutes in phosphate-buffered saline (PBS) and then
reacted with a rabbit anti-goat secondary antibody (1:5000;
Beyotime, Shanghai, China). For tissues, β-actin antibody
(1:1000; Santa Cruz Biotechnologies, USA) was recubated
to ensure equal loading. At the end, the membrane was
covered completely with an equal amount of enhancer
and peroxide solution from an ECL plus Kit (Beyotime,
Shanghai, China) for 1 minute, and then all membranes
were exposed to the film. The density of the band was
quantified using Gel Image System (Tanon, Shanghai,
China). The fixed amount of 1 ng purified EL standard
(R&D systems, Inc., USA) was used as a positive control
for calibration. With consideration the variations in urine
formation and excretion, densitometry of EL from urine
was expressed relative to urinary creatinine concentrations.
Immunohistochemistry
For measuring the expression levels of EL in cancer
versus adjacent noncancerous control tissues, both types
of tissues were fixed for 12–16 hours in 4% para-
formaldehyde (pH 7.0), embedded in paraffin and cut
into 4 μm thick sections. Plus slides were baked at 60°C
for 30 minutes. Paraffin was removed using xylene for
30 minutes, and the sections were rehydrated through a
series of alcohol solutions before treatment with 1 mM
citric acid, pH 6.0, at 100°C for 5 minutes and with 1%
H2O2 for 30 minutes. After being washed with distilled
water, sections were incubated at room temperature with
5% porcine sera in PBS for 30 minutes and EL antibody
(1:400; Santa Cruz Biotechnologies, USA) diluted in PBS
overnight at 4°C, washed three times for 5 minutes in
PBS. Bound antibodies were visualized with the color re-
agent Diaminobenzidine (Bios, Beijing, China). The sec-
tions were counterstained with Mayer’s haematoxylin.
Two pathologists without knowledge of the patients’
clinical status evaluated all of the stained sections inde-
pendently. The cells were counted at high magnification
in each case (×400), and the percentage of positively
staining cells was calculated. The proportion of cells
exhibiting EL expression was categorized as follows:
0 = less than 10%; 1 =11% -50%; 2 =51% -75%; 3 =more
than 75%. The staining intensity was categorized by rela-
tive intensity as follows: 0 = negative; 1 = weak; 2 = inter-
mediate; 3 = strong staining. The proportion and intensity
Table 1 The information of healthy volunteers and
patients involved in this study
Characteristics Tissue Serum Urine
Gastric cancer 12 12 90
Mean age (range) 60(42–76) 63(84–39) 60(31–85)
Gender
Male 6 7 67
Female 6 5 23
Tumor location
Cardia 3 2 39
Body 5 6 26
Antrum 3 4 16
Diffuse 1 0 9
Operation
Total Gastrectomy 4 5 29
Subtotal Gastrectomy 8 7 61
Lauren classification
Intestinal 5 4 39
Diffuse 7 8 51
Histology type
High or moderate 5 5 43
Poor or undifferentiated 7 7 47
Tumor stages
Ι and ΙΙ 2 4 31
ΙΙΙ and ΙV 10 8 59
Depth of invasion
T1 and T2 5 9 30
T3 and T4 7 3 60
Node status
N0 3 3 29
N1 and N2 9 9 61
Metastasis status
M0 5 10 71
M1 7 2 19
Lung cancer - - 9
Mean age (range) 46(42–57)
Colon cancer - - 10
Mean age (range) 53(46–65)
Rectum cancer - - 9
Mean age (range) 62(47–78)
Healthy 12 12 57
Mean age (range) 60(42–76) 54(41–72) 47 (29–76)
Gastritis/Chronic inflammation - - 2
Mean age (range) 56 (43–69)
Gastritic leiomyoma 2
Mean age (range) - - 56 (51–62)
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scores were then multiplied to have a total score index.
Per statistical analysis, scores lower than 2 were consid-
ered negative, and scores of 2 or higher were considered
positive.
Statistical analysis
The chi-square test and Wilcoxon’s signed rank test
were used to analyze the expression levels of EL in the
paired cancer and noncancerous tissue samples. To
analyze the difference of EL expression levels in the
serum and urine samples between gastric cancer patients
and the healthy controls respectively, Mann–Whitney
test was used. The chi-square test was employed to
evaluate the relationship between urinary EL expression
levels and clinicopathological variables. The discerning
power of the expression levels of EL in urine between
samples from the cancer and control group was exam-
ined using the receiver operating characteristic (ROC)
curve and the area under the ROC curve (AUC). All
tests were two tailed and a P-value < 0.05 was consi-
dered statistically significant. All statistical analyses were
performed using the GraphPad Prism 5 statistical
software.
Results
EL expression levels in urine
For the semi-quantitative analysis of urine proteins, we
used relative EL expression levels with respect to that of
the urinary creatinine in each sample to normalize EL
expression across different urine samples. We observed
a clear separation between the EL expression levels in
the urine samples of 90 gastric cancer patients (1.39 ±
0.68) and of 57 healthy volunteers (0.14 ± 0.32). We ob-
served an approximately 9.9 fold average decrease of EL
protein levels in the urine samples of gastric cancer pa-
tients compared to healthy controls (P < 0.0001). The re-
sults can be seen in Figure 1A and Figure 2A. We have
plotted the ROC curve for the classification accuracy
using the EL expression levels across all these urine sam-
ples, to provide an overall view of the discerning power
of the protein. Note that the AUC provides a widely ac-
cepted index for measuring the quality of the underlying
classifier with AUC = 1.0 representing perfect classifica-
tion and AUC = 0.5 representing no separation. EL has
achieved an AUC value at 0.967 with the 95% confidence
interval (CI) being [0.942-0.993], indicating that urinary
EL can serve as a highly promising gastric cancer bio-
marker for the diagnostic purpose (Figure 2B).
We note that the EL band in Western blot was absent
in urine samples of 71 of the 90 gastric cancer patients
and all of the 57 healthy volunteers have the EL band in
their urine samples. Using absence/presence of the EL
band as the cutoff in calling a person having stomach
cancer or not, the above data gives rise to a calling sensi-
tivity at 79% [95% CI, 0.690-0.867] and specificity at
100% [95% CI, 0.937-1.000].
We then examined the EL expression levels in urine
samples of the gastric cancer patients and its relation-
ship to the various clinicopathological factors, namely
gender, histology differentiation, tumor stage, invasion,
and metastasis status. No significant statistical relation-
ships between the EL expression levels and any of these
factors can be detected. The correlation between urinary
EL expression levels and the clinicopathological factors
are presented in Table 2.
We have also checked if EL is specific to gastric can-
cer. As an initial effort, we have examined the EL ex-
pression levels in urine samples of three other cancer
Figure 1 A representative Western blot analysis of EL protein abundance. Positive control lane (+) contained the commercial EL standard
product, which was used to normalize the signal response across all gels. (A), The abundance of EL protein on urine samples; (B), EL abundance
on cancer tissue samples and matching noncancerous samples from gastric cancer patients with no treatment. The β-actin serves as an internal
loading control for estimating the relative protein abundance levels; (C), EL protein abundance in serum samples.
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types (lung, colon and rectum cancers) and benign le-
sions (gastritis and gastric leiomyoma). The test was
done on urine samples of 9 lung cancer, 10 colon cancer,
10 rectum cancer, 2 gastritis, and 2 gastric leiomyoma
patients. Clearly we can see that 9 out of 9, 9 out of 10,
10 out of 10, 2 out of 2, and 2 out 2 samples have the
EL band in the urine samples of lung cancers, colon can-
cers, rectum cancer, gastritis and gastric leiomyoma pa-
tients, respectively (Figure 3). While this result does not
guarantee that the lack of EL in urine is an indicator of
only gastric cancer, it does strongly suggest that EL is
highly specific. Larger tests will be done in our follow-
up study, which will involve substantially more patients
of other diseases possibly related to gastric cancer, such
as pancreatic cancer and esophagus cancer.
EL expression levels in tissues and sera
The study indicates that the EL protein is absent in gas-
tric cancer urine samples. Considering that urine con-
tains both protein secreted from urothelium as well as
proteins from the plasma or cell lysis, we have also ex-
amined the EL expression levels in tissue or serum of
gastric cancer patients, aiming to infer the reasons for
this observed absence. Western blot was carried out to
measure the EL expression levels in cancer tissue sam-
ples and matching noncancerous samples from 12 un-
treated gastric cancer patients (Figure 1B). No significant
difference in the expression levels of EL was observed
between the gastric cancer tissue samples and the match-
ing noncancerous samples (Wilcoxon’s signed rank test,
P =0.90).
In immunohistochemical staining experiments, we
found that the brown granules predominantly appeared
in the cytoplasm (Figure 4). Positive expression of the
EL protein was found in 58% (7/12) of gastric cancer
and in 67% (8/12) of gastric adjacent noncancerous sam-
ples (Table 3). There was no difference in the expression
levels of this protein between the gastric cancer and
the matching noncancerous tissues (chi-square test,
Figure 2 Urinary EL protein abundances in gastric cancer patients versus healthy controls. Each data point is one individual. (A), EL
abundance in samples of gastric cancer patients significantly lower than that in samples from healthy controls; (B), ROC curves of urinary EL
protein. The AUC value was 0.967.
Table 2 Correlation between urinary EL expression and
clinicopathological features
Clinicopathological (n) EL absent (%) EL present (%) P
n = 71 n = 19
Gender
Male, (67) 51 (72) 16 (84) 0.27
Female, (23) 20 (28) 3 (16)
Histological type
High or moderate, (43) 31 (44) 12 (63) 0.13
Poor or undifferentiated, (47) 40 (56) 7 (37)
Lauren classification
Intestinal, (39) 29 (41) 10 (53) 0.36
Diffuse, (51) 42 (59) 9 (47)
Tumor stages
Ι and ΙΙ, (31) 22 (31) 9 (47) 0.18
ΙΙΙ and ΙV, (59) 49 (69) 10 (53)
Depth of invasion
T1 and T2, (30) 21 (30) 9 (47) 0.14
T3 and T4, (60) 50 (70) 10 (53)
Node status
Absent, (29) 23 (32) 6 (32) 0.95
Present, (61) 48 (68) 13 (68)
Metastasis status
M0 (71) 55 (77) 16 (84) 0.52
M1 (19) 16 (23) 3 (16)
Dong et al. Diagnostic Pathology 2013, 8:45 Page 5 of 9
http://www.diagnosticpathology.org/content/8/1/45
P =0.67). We also examined any possible relationship be-
tween the EL expression levels and potentially relevant
clinicopathological factors mentioned earlier. No relation-
ship was detected. The results are presented in Table 4.
We then measured the EL expression levels in sera of
the 12 gastric cancer patients versus those of 12 healthy
people (Figure 1C). It can be seen that there is no clear
distinction between the cancer samples and the healthy
control (Mann–Whitney test, P = 0.79). We note that
the EL expression levels have a wide range distribution
in both sets of samples.
Discussion
In our previous study, we developed a novel computa-
tional method and applied it to predict that EL could
potentially serve as a highly promising diagnostic urinary
marker for gastric cancer. Here, we have further con-
firmed this prediction on larger sample set, and in
addition we discovered that the EL protein is highly spe-
cific to gastric cancer.
EL is a new member of the triglyceride lipase gene
family, and has high sequence homology with lipopro-
tein lipase (LPL) (45%), hepatic lipase (HL) (41%) and
pancreatic lipase (PL) (21%) [19,20]. EL has primarily a
phospholipase and has some triglyceride lipase activity,
which has an important role in plasma high-density lipo-
proteins metabolism and atherosclerosis development
[21-25]. Several studies have shown that LPL plays
an important role in carcinogenesis, including colorec-
tal and pancreatic cancers, and lung cancer [26,27].
Figure 3 EL abundances in urine samples of other cancer types and benign lesions. (A), Nine lung cancer samples; (B), Ten colon cancer
samples; (C), Ten rectal cancers samples; (D), Two gastritis and two gastritic leiomyoma samples. (+) The positive control lane.
Figure 4 Immunohistochemical analysis of EL in tissues of gastric cancer and matching noncancerous samples. The brown granules of
EL predominantly appeared in cytoplasm. Adjacent noncancerous tissues stained with (A) (×400). Cancer tissues stained with (B) (×400).
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However, EL has not been reported to be associated with
any cancer except for testicular germ cell tumors, while
the mechanism there is unclear [28].
The discovery that the expression levels of EL is sig-
nificantly reduced in urine of gastric cancer patients,
while showing no difference between the correspond-
ing serum samples as well as tissue samples is very in-
triguing. One potential reason could be due to the
properties of the glomerular filtration system. It is
known that plasma proteins were filtered though the
glomeruli on the basis of their sizes, charges and struc-
ture shape [29]. Small and positively charged mole-
cules were more easily filtered into urine than large
and negatively charged proteins. The sequence of EL
has a number of positively charged clusters [30], which
may be a reason that it can be filtered out in healthy
people’s urine. However, the microenvironment of the
cancer cells tend to be more acidic [31], which may
potentially change positively charged clusters of ELs to
negative ones, hence preventing the molecules from
being filtered into the urine. Certainly, the precise
reason is yet to be understood, and warrants further
studies.
Urine is an ideal non-invasive source for cancer de-
tection. However, it should be noted that urine has a
high degree of variability in protein concentrations
throughout a day, which can be influenced by various
factors (age, diet, and collection time). For this reason,
it is a key to normalize the protein concentration in
urine when measuring the expression levels of protein.
Therefore, we used the relative EL expression levels
with respect to that of the urinary creatinine in each
sample to normalize EL expression levels across differ-
ent urine samples. The results of this study suggest that
the loss of urinary EL expression can provide a prelim-
inary indication of gastric cancer during large-scale
screening and more direct examinations such as gas-
troscopy and pathology test on the biopsy sample will
be needed for the final diagnosis. Many studies report
that diagnostic biomarker may be a useful prognostic
and survival indicator for gastric cancers [32-34]. It was
not only to predict the prognosis information of cancer
patients, but also to provide the treatment strategy for
the physician. So we examined the correlation between
EL expression levels and the clinicopathological charac-
teristics in gastric cancer. Although EL makes a prom-
ising diagnostic marker for gastric cancer, we did not
find any strong relationships between the EL expression
level and the tumor’s prognostic clinicopathological
characteristics such as tumor type, invasion and TNM
staging. In addition, because of the short term of study
and lack of regular follow up of patients, we can not as-
sess survival rate in this study. The limited existing data
showed that EL expression can not be used as a useful
prognostic and survival indicators for gastric cancer.
The next study, we aimed to investigate the EL protein
expression in larger numbers of patients with different
tumors and its follow up studies, and to explore the
exactly mechanism of EL’s role in the carcinogenesis of
gastric cancer.
Conclusion
In conclusion, although it is not linked to tumor stage
or grade, urinary EL could be a highly promising gastric
cancer biomarker that may be applicable to large-scale
screenings with high diagnostic fidelity.
Table 4 EL expression and clinicopathological factors in
gastric cancer tissues
Clinicopathological n EL P
Negative Positive
Gender
Male 6 2 4 0.56
Female 6 3 3
Age (year)
≤50 3 1 2 0.74
>50 9 4 5
Lauren classification
Intestinal 5 3 2 0.28
Diffuse 7 2 5
Histological type
Highly differentiated 1 1 0 0.36
Moderately differentiated 4 2 2
Poorly differentiated 7 2 5
Tumor stages
I and II 2 1 1 0.79
III and IV 10 4 6
Depth of invasion
T1 and T2 5 2 3 0.92
T3 and T4 7 3 4
Lymph node metastasis
Positive 3 1 2 0.74
Negative 9 4 5
Table 3 EL expression in gastric cancer and adjacent
noncance rous samples
n The expression of EL protein P
Negative Positive
Adjacent control 12 4(33%) 8 (67%) 0.67
Gastric cancer 12 5(42%) 7 (58%)
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